Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide

Am J Vet Res. 2017 Jul;78(7):862-866. doi: 10.2460/ajvr.78.7.862.

Abstract

OBJECTIVE To characterize pharmacokinetics of cyclophosphamide and 4-hydoxycyclophosphamide (4-OHCP) in the plasma of healthy cats after oral, IV, and IP administration of cyclophosphamide. ANIMALS 6 healthy adult cats. PROCEDURES Cats were randomly assigned to receive cyclophosphamide (200 mg/m2) via each of 3 routes of administration (oral, IV, and IP); there was a 30-day washout period between successive treatments. Plasma samples were obtained at various time points for up to 8 hours after administration. Samples were treated with semicarbazide hydrochloride to trap the 4-OHCP in stable form, which allowed for cyclophosphamide and trapped 4-OHCP to be simultaneously measured by use of tandem mass spectrometry. Pharmacokinetic parameters were determined from drug concentration-versus-time data for both cyclophosphamide and 4-OHCP. RESULTS Cyclophosphamide was tolerated well regardless of route of administration. Pharmacokinetic parameters for 4-OHCP were similar after oral, IV, and IP administration. Area under the concentration-time curve for cyclophosphamide was lower after oral administration than after IV or IP administration. CONCLUSIONS AND CLINICAL RELEVANCE Cyclophosphamide can be administered interchangeably to cats as oral, IV, and IP formulations, which should provide benefits with regard to cost and ease of administration to certain feline patients.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Intravenous / veterinary
  • Administration, Oral
  • Animals
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Agents, Alkylating / pharmacokinetics*
  • Area Under Curve
  • Biological Availability
  • Cats / metabolism*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / analogs & derivatives*
  • Cyclophosphamide / pharmacokinetics*
  • Female
  • Half-Life
  • Injections, Intraperitoneal / veterinary
  • Male
  • Tandem Mass Spectrometry / veterinary

Substances

  • Antineoplastic Agents, Alkylating
  • 4-hydroxycyclophosphamide
  • Cyclophosphamide